Literature DB >> 20211436

Metabolic therapy at the crossroad: how to optimize myocardial substrate utilization?

Stephen C Kolwicz1, Rong Tian.   

Abstract

There has been growing interest in targeting myocardial substrate metabolism for the therapy of cardiovascular and metabolic diseases. This is largely based on the observation that cardiac metabolism undergoes significant changes during both physiologic and pathologic stresses. In search for an effective therapeutic strategy, recent studies have focused on the functional significance of the substrate switch in the heart during stress conditions, such as cardiac hypertrophy and failure, using both pharmacologic and genetic approaches. The results of these studies indicate that both the capacity and the flexibility of the cardiac metabolic network are essential for normal function; thus, their maintenance should be the primary goal for future metabolic therapy. (c) 2009 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 20211436      PMCID: PMC2836268          DOI: 10.1016/j.tcm.2009.12.005

Source DB:  PubMed          Journal:  Trends Cardiovasc Med        ISSN: 1050-1738            Impact factor:   6.677


  69 in total

1.  Preservation of glucose metabolism in hypertrophic GLUT4-null hearts.

Authors:  A E Stenbit; E B Katz; J C Chatham; D L Geenen; S M Factor; R G Weiss; T S Tsao; A Malhotra; V P Chacko; C Ocampo; L A Jelicks; M J Charron
Journal:  Am J Physiol Heart Circ Physiol       Date:  2000-07       Impact factor: 4.733

2.  Constitutive regulation of cardiac fatty acid metabolism through peroxisome proliferator-activated receptor alpha associated with age-dependent cardiac toxicity.

Authors:  K Watanabe; H Fujii; T Takahashi; M Kodama; Y Aizawa; Y Ohta; T Ono; G Hasegawa; M Naito; T Nakajima; Y Kamijo; F J Gonzalez; T Aoyama
Journal:  J Biol Chem       Date:  2000-07-21       Impact factor: 5.157

3.  Responses of GLUT4-deficient hearts to ischemia underscore the importance of glycolysis.

Authors:  R Tian; E D Abel
Journal:  Circulation       Date:  2001-06-19       Impact factor: 29.690

4.  Metabolic gene expression in fetal and failing human heart.

Authors:  P Razeghi; M E Young; J L Alcorn; C S Moravec; O H Frazier; H Taegtmeyer
Journal:  Circulation       Date:  2001-12-11       Impact factor: 29.690

5.  Altered metabolism causes cardiac dysfunction in perfused hearts from diabetic (db/db) mice.

Authors:  D D Belke; T S Larsen; E M Gibbs; D L Severson
Journal:  Am J Physiol Endocrinol Metab       Date:  2000-11       Impact factor: 4.310

6.  Sarcoplasmic reticulum function and carnitine palmitoyltransferase-1 inhibition during progression of heart failure.

Authors:  H Rupp; R Vetter
Journal:  Br J Pharmacol       Date:  2000-12       Impact factor: 8.739

7.  The cardiac phenotype induced by PPARalpha overexpression mimics that caused by diabetes mellitus.

Authors:  Brian N Finck; John J Lehman; Teresa C Leone; Michael J Welch; Michael J Bennett; Attila Kovacs; Xianlin Han; Richard W Gross; Ray Kozak; Gary D Lopaschuk; Daniel P Kelly
Journal:  J Clin Invest       Date:  2002-01       Impact factor: 14.808

8.  Reactivation of peroxisome proliferator-activated receptor alpha is associated with contractile dysfunction in hypertrophied rat heart.

Authors:  M E Young; F A Laws; G W Goodwin; H Taegtmeyer
Journal:  J Biol Chem       Date:  2001-09-26       Impact factor: 5.157

9.  Peroxisome proliferator-activated receptor gamma coactivator-1 promotes cardiac mitochondrial biogenesis.

Authors:  J J Lehman; P M Barger; A Kovacs; J E Saffitz; D M Medeiros; D P Kelly
Journal:  J Clin Invest       Date:  2000-10       Impact factor: 14.808

10.  Cardiac hypertrophy with preserved contractile function after selective deletion of GLUT4 from the heart.

Authors:  E D Abel; H C Kaulbach; R Tian; J C Hopkins; J Duffy; T Doetschman; T Minnemann; M E Boers; E Hadro; C Oberste-Berghaus; W Quist; B B Lowell; J S Ingwall; B B Kahn
Journal:  J Clin Invest       Date:  1999-12       Impact factor: 14.808

View more
  18 in total

1.  Kruppel-like factor 15 is a critical regulator of cardiac lipid metabolism.

Authors:  Domenick A Prosdocimo; Priti Anand; Xudong Liao; Han Zhu; Shamanthika Shelkay; Pedro Artero-Calderon; Lilei Zhang; Jacob Kirsh; D'Vesharronne Moore; Mariana G Rosca; Edwin Vazquez; Janos Kerner; Kemal M Akat; Zev Williams; Jihe Zhao; Hisashi Fujioka; Thomas Tuschl; Xiaodong Bai; P Christian Schulze; Charles L Hoppel; Mukesh K Jain; Saptarsi M Haldar
Journal:  J Biol Chem       Date:  2014-01-08       Impact factor: 5.157

2.  Deficiency of cardiac Acyl-CoA synthetase-1 induces diastolic dysfunction, but pathologic hypertrophy is reversed by rapamycin.

Authors:  David S Paul; Trisha J Grevengoed; Florencia Pascual; Jessica M Ellis; Monte S Willis; Rosalind A Coleman
Journal:  Biochim Biophys Acta       Date:  2014-03-12

3.  Intravenous (-)-epicatechin reduces myocardial ischemic injury by protecting mitochondrial function.

Authors:  Katrina Go Yamazaki; Aleksander Y Andreyev; Pilar Ortiz-Vilchis; Susanna Petrosyan; Ajit S Divakaruni; Sandra E Wiley; Christine De La Fuente; Guy Perkins; Guillermo Ceballos; Francisco Villarreal; Anne N Murphy
Journal:  Int J Cardiol       Date:  2014-05-15       Impact factor: 4.164

4.  A new strategy to decrease cardiac injury in aged heart following ischaemia-reperfusion: enhancement of the interaction between AMPK and SIRT1.

Authors:  Qun Chen; Edward J Lesnefsky
Journal:  Cardiovasc Res       Date:  2018-05-01       Impact factor: 10.787

5.  Diet-induced lethality due to deletion of the Hdac3 gene in heart and skeletal muscle.

Authors:  Zheng Sun; Nikhil Singh; Shannon E Mullican; Logan J Everett; Li Li; Lijun Yuan; Xi Liu; Jonathan A Epstein; Mitchell A Lazar
Journal:  J Biol Chem       Date:  2011-08-01       Impact factor: 5.157

Review 6.  Kruppel-like factors in muscle health and disease.

Authors:  Domenick A Prosdocimo; M Khaled Sabeh; Mukesh K Jain
Journal:  Trends Cardiovasc Med       Date:  2014-11-15       Impact factor: 6.677

7.  Mitochondrial approaches to protect against cardiac ischemia and reperfusion injury.

Authors:  Amadou K S Camara; Martin Bienengraeber; David F Stowe
Journal:  Front Physiol       Date:  2011-04-12       Impact factor: 4.566

8.  Rearrangement of energetic and substrate utilization networks compensate for chronic myocardial creatine kinase deficiency.

Authors:  Petras P Dzeja; Kirsten Hoyer; Rong Tian; Song Zhang; Emirhan Nemutlu; Matthias Spindler; Joanne S Ingwall
Journal:  J Physiol       Date:  2011-08-30       Impact factor: 5.182

Review 9.  Remodeling of glucose metabolism precedes pressure overload-induced left ventricular hypertrophy: review of a hypothesis.

Authors:  Bijoy K Kundu; Min Zhong; Shiraj Sen; Giovanni Davogustto; Susanna R Keller; Heinrich Taegtmeyer
Journal:  Cardiology       Date:  2015-03-12       Impact factor: 1.869

10.  Mesenchymal stem cell transplantation for the infarcted heart: a role in minimizing abnormalities in cardiac-specific energy metabolism.

Authors:  Curtis C Hughey; Virginia L Johnsen; Lianli Ma; Freyja D James; Pampee P Young; David H Wasserman; Jeffrey N Rottman; Dustin S Hittel; Jane Shearer
Journal:  Am J Physiol Endocrinol Metab       Date:  2011-10-04       Impact factor: 4.310

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.